Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
Status:
Completed
Trial end date:
2021-05-12
Target enrollment:
Participant gender:
Summary
This study is being conducted to assess the effectiveness of intermediate versus prophylactic
doses of anticoagulation (blood thinners) in patients critically ill with COVID-19 in the
intensive care units (ICUs) throughout the hospital. Anticoagulation is part of the patient's
usual standard of care but determining the dose of anticoagulation is based on physician
preference. The investigators are conducting this study (a randomized trial with adaptive
design employing cluster randomization) with the support of all of the ICUs to collect data
in order to determine what should be the standard of care in terms of anticoagulation in
these critically ill patients. The patients care will not be altered other than the choice of
anticoagulation (both approved and used throughout the hospital as standard of care) based on
the ICU bed they are assigned. Patient data will be collected until discharge.